Given PTPN22’s role in regulating T cells and macrophages in tumor defense, we propose that PTPN22 inhibitors could emerge as a unique form of cancer immunotherapy with broad immunomodulatory effects, especially when combined with other immunotherapeutic strategies. The gene discussed is PTPN22; the disease is neoplasm.